Q-Line Biotech
- P/E
- 24.98
Key Fundamentals
SMEHealthcare Equipment & SuppliesHealthcarePrice-based figures as of · TTM
- ROCE
- 22.40%
- Debt to Equity
- 0.91
- EPS (TTM)
- ₹21.10
- Book Value
- ₹209.24
- Market Cap
- —
- P/E (TTM)
- 24.98
- P/B
- 2.52
- ROE
- 26.00%
- Dividend Yield
- 0.00%
- EBITDA
- ₹104 Cr
- 52W High
- ₹735.00
- 52W Low
- ₹431.00
- Day Range
- ₹510.00 – ₹537.35
- Volume
- 69,400
Peer Comparison
Healthcare › Medical Equipment › Medical Equipment & Supplies
| ₹1,381.80 | 123.38 | ₹15,607 Cr | 11.63 | 0.00% | 13.80% | 18.00% | ₹1,077 Cr | ₹125 Cr | |
| ₹1,586.80 | 51.04 | ₹15,325 Cr | 5.18 | 0.23% | 9.02% | 12.50% | ₹1,997 Cr | ₹313 Cr | |
| ₹25.23 | 66.39 | ₹1,611 Cr | 3.61 | 0.20% | 8.91% | 11.40% | ₹367 Cr | ₹24 Cr | |
| ₹311.10 | 148.85 | ₹1,603 Cr | 2.61 | 0.67% | 2.44% | 4.59% | ₹441 Cr | ₹11 Cr | |
| Q-Line Biotech (this company) | ₹527.15 | 24.98 | ₹1,243 Cr | 2.52 | 0.00% | 26.00% | 22.40% | ₹201 Cr | ₹34 Cr |
| ₹188.71 | 33.64 | ₹1,017 Cr | 4.27 | 0.00% | 14.80% | 15.00% | ₹287 Cr | ₹31 Cr | |
| ₹608.10 | — | ₹868 Cr | 5.64 | 0.00% | 16.90% | 18.90% | — | — | |
| Median 7 companies | ₹527.15 | 58.72 | ₹1,603 Cr | 4.27 | 0.00% | 13.80% | 15.00% | ₹404 Cr | ₹33 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Key Insights
No strengths listed
Weaknesses
1- Debtor days have increased from 92.7 to 134 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 10 | 7 | 2 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 8 | 2 | 0 |
Oscillators
Neutral
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 37.12
- Neutral
- MACD (12,26,9)
- −32.11
- Bearish
- SMA (50)
- 618.13
- Bearish
- SMA (200)
- —
- Neutral
As of
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 3Y | +23.18% |
|---|---|
| 1Y | +9.27% |
Net profit
| 3Y | +20.51% |
|---|---|
| 1Y | +194.74% |
Operating cash flow
| 3Y | −13.82% |
|---|---|
| 1Y | −5.88% |
Operating margin· change in pp
| 3Y | +10.07 pp |
|---|---|
| 1Y | +5.97 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2023 | ₹183 Cr |
|---|---|
| Mar 2024 | ₹203 Cr |
| Mar 2025 | ₹313 Cr |
| Mar 2026 | ₹342 Cr |
Net profit by year
| Mar 2023 | ₹32.00 Cr |
|---|---|
| Mar 2024 | ₹34.00 Cr |
| Mar 2025 | ₹19.00 Cr |
| Mar 2026 | ₹56.00 Cr |
Quarterly Results
₹ Cr| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 217 | 198 |
| Expenses | 172 | 136 |
| Operating Profit | 45 | 62 |
| OPM % | 21% | 31% |
| Other Income | −11 | 2 |
| Interest | 8 | 11 |
| Depreciation | 3 | 7 |
| PBT | 22 | 46 |
| Tax % | 71% | 26% |
| Net Profit | 9 | 34 |
| EPS (₹) | 56.13 | 21.14 |
Profit & Loss
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 183 | 203 | 313 | 342 |
| Expenses | 149 | 165 | 242 | 244 |
| Operating Profit | 34 | 38 | 71 | 98 |
| OPM % | 18% | 19% | 23% | 29% |
| Other Income | 2 | 3 | −14 | 5 |
| Interest | 4 | 6 | 15 | 19 |
| Depreciation | 2 | 4 | 7 | 11 |
| PBT | 30 | 31 | 35 | 73 |
| Tax % | 28% | 29% | 55% | 23% |
| Net Profit | 32 | 34 | 19 | 56 |
| EPS (₹) | 204 | 219 | 122 | 34.24 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 16 |
| Reserves | 126 | 160 | 188 | 230 |
| Borrowings | 74 | 97 | 166 | 225 |
| Other Liabilities | 51 | 81 | 99 | 87 |
| Total Liabilities | 252 | 339 | 455 | 559 |
| Fixed Assets | 23 | 60 | 91 | 158 |
| CWIP | 12 | 19 | 63 | 19 |
| Investments | 16 | 29 | 0 | 0 |
| Other Assets | 201 | 232 | 302 | 381 |
| Total Assets | 252 | 339 | 455 | 559 |
Cash Flow
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 25 | −24 | 17 | 16 |
| Investing | −26 | −45 | −77 | −29 |
| Financing | 26 | 17 | 53 | 42 |
| Net Cash Flow | 25 | −52 | −7 | 29 |
| Free Cash Flow | −5 | −72 | −53 | −19 |
| CFO/OP | 111 | −39 | 36 | 43 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 66 | 47 | 96 | 134 |
| Inventory Days | 180 | 413 | 225 | 258 |
| Days Payable | 164 | 232 | 139 | 142 |
| Cash Conversion Cycle | 82 | 228 | 183 | 251 |
| Working Capital Days | −44 | 51 | 45 | 62 |
| ROCE % | — | 16% | 24% | 22% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Q-Line Biotech insights
55 extracted metrics across FY23–FY26.
Documents
- Concall · Jun 2026Transcript PPT
- 25 Aug 2026
- 26 Jun 2026
- 9 Apr 2026
- 16 Mar 2026
- 4 Sep 2025
- 1 Oct 2026
- 1 Oct 2026
- 30 Sep 2026
- 28 Sep 2026
Frequently Asked Questions about Q-Line Biotech
What does Q-Line Biotech Ltd do?
Where is Q-Line Biotech Ltd (QLINE) listed?
Which sector does Q-Line Biotech Ltd belong to?
What is the PE ratio of Q-Line Biotech Ltd?
What is the 52-week high and low of Q-Line Biotech Ltd?
What is the Return on Equity (ROE) of Q-Line Biotech Ltd?
Company Information
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/QLINE.md for Q-Line Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.